A medic holds a vial of the AstraZeneca Covid-19 vaccine in Hanoi. Photo by VnExpress/Giang Huy |
The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from Covid-19.
After a three-dose course of the vaccine, neutralizing levels against Omicron were similar to those against the virus's Delta variant after two doses, the company added.
The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.